2022, FDA and Immunization - Pharmacy Technician Pulse

Pneumococcal Vaccine Rates Low Despite Updated Recommendations

Drug Topics

JULY 11, 2025

In 2022, the Advisory Committee on Immunization Practices (ACIP) published updated pneumococcal vaccine recommendations. million adult patients who were enrolled in a health plan as of January 2022 that contributed data to the Optum database. Of those, 38% had evidence of pneumococcal vaccination prior to January 2022.

Vaccines

Vaccines Immunization Specialty Pharmacies Compounding

FDA Approves Insulin Aspart-Xjhz as First Interchangeable Biosimilar to NovoLog

Drug Topics

JULY 21, 2025

The FDA approved insulin aspart-xjhz (Kirsty) 100 units/mL as the first and only interchangeable biosimilar to insulin aspart (NovoLog). 1 The FDA approves Kirsty, an interchangeable biosimilar insulin, enhancing diabetes treatment options and accessibility for patients. Sign up today for our free Drug Topics newsletter.

FDA

FDA Specialty Pharmacies Compounding Hospitals

Pharmacist Involvement Helps Reduce Time to A1c Target

Drug Topics

JUNE 13, 2025

In 2022, the estimated cost of those diagnosed as having diabetes was $413 billion. 2022 Jun 20;15:1911-1923. Additional advantages include fewer emergency visits, hospitalizations, medication adherence, and associated cost savings. 2 “Prevalence of diabetes in the United States continues to rise, affecting an estimated 38.4

Compounding

Compounding Specialty Pharmacies Independent Pharmacies Immunization

CGM Usage Improves Glycemic, Psychosocial Outcomes for Type 1 Diabetes | ADA 2025

Drug Topics

JUNE 23, 2025

Updated September 12, 2022. June 20 to 23, 2025. Chicago, Illinois. Overcoming Barriers and Obstacles to Adopting Diabetes Devices (ONBOARD). ClinicalTrials.gov identification: NCT04161131. Accessed June 23, 2025.

Compounding

Compounding Specialty Pharmacies Independent Pharmacies Immunization

Financial Burden for Patients With Type 2 Diabetes Higher Than Those Without

Drug Topics

JULY 31, 2025

In 2022, the total estimated cost of diagnosed diabetes was $412.9 1 “Patients with diabetes were more likely to experience 2 of the 7 financial outcomes compared with 1.2 outcomes of patients without diabetes.” billion in the US, including $306.6 billion for direct medical costs and $106.3 billion for indirect costs. JAMA Netw Open.

Specialty Pharmacies

Specialty Pharmacies Compounding Independent Pharmacies Immunization

Help Turn Occasional Shoppers into Loyal Customers by Investing in the Front End

Drug Topics

JULY 10, 2025

Daymon, 2022 Private Brand Intelligence Report, May 2023. Our team will be on site to share insights and showcase our portfolio of more than 500 health and wellness OTC products through the Foster & Thrive brand name, including affordable and eco-friendly offerings that reflect today’s consumer priorities. Fred Reichheld. April 2025.

Health and Personal Care Stores

Health and Personal Care Stores Independent Pharmacies Labelling Specialty Pharmacies

4 vitamins for post-COVID fatigue

The Checkup by Singlecare

NOVEMBER 26, 2024

A 2022 study found that both B12 and B5 had protective effects against COVID infection, while a 2020 study found that vitamin B12 (when combined with vitamin D and magnesium) improved outcomes for elderly patients hospitalized with COVID-19. Vitamin C: Vitamin C is well known for its positive effects on the immune system.

Immunization

Immunization Hospitals FDA

COVID-19 Pandemic Reduced Gaps in Pneumococcal Vaccination in Medicare Enrollees, But Lowered Overall Uptake

Pharmacy Times

JULY 25, 2025

According to 2022 data from a National Health Interview Survey of US adults ages 18 and older, just 23.0% Despite their purported efficacy and safety, uptake remains below target levels. of individuals ages 19 to 64 at increased risk for pneumococcal disease and 64.0% 1 Medicare enrollees were examined first.

Vaccines

Vaccines Compounding Pharmacies Immunization Compounding

The Changing Landscape of Pharmacy Accessibility

Pharmacy Times

JULY 22, 2025

Image Credit: Elena | stock.adobe.com A 2022 study reported that approximately 90% of the United States population lives within 5 miles of a pharmacy. The lack of access to immunization services may lead to lower vaccination rates and vulnerabilities to infectious diseases in these communities.

Mail-Order Pharmacies

Mail-Order Pharmacies Community Pharmacies Compounding Pharmacies Immunization

Under the Weather: Unpacking the Impact of the 2024-2025 Influenza Season

Pharmacy Times

JULY 21, 2025

Reduced immunity from COVID-19 precautions and low vaccination rates, especially among children and vulnerable groups, worsened the influenza season's impact. Systemic inequities, misinformation, and geographic disparities hindered vaccination efforts, with significant coverage gaps among racial and rural populations.

Vaccines

Vaccines Immunization Hospitals Compounding Pharmacies

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Pharmacy Times

JUNE 9, 2025

Study Overview Researchers conducted a retrospective chart review of 80 patients aged 12 or older within Intermountain Health who were diagnosed with asthma between December 2022 and December 2023. To ensure continuity of care, patients included had seen a primary care provider both in the year prior to and following their diagnosis.

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Chemotherapy

Pharmacists Push Forward: Innovative Clinical Solutions Highlighted at McKesson ideaShare 2025

Pharmacy Times

JULY 12, 2025

4 Novak added that these services align well with appointment-based models and can be layered with immunizations, chronic disease monitoring, and medication therapy management. December 2022. Addressing Barriers and Finding Solutions Despite the promise of these services, challenges remain. News release. May 9, 2019. doi:10.2105/AJPH.2018.203609

Independent Pharmacies

Independent Pharmacies Hospitals Compounding Pharmacies Immunization

Transitions of Care Pharmacists Mitigate Readmission Rates for COPD

Pharmacy Times

JUNE 23, 2025

Its average fiscal year 2022 readmission rate was 23.7%, exceeding the 19.6% The hospital-approved protocol, created in June 2022, granted TOC pharmacists prescribing authority for guideline-directed medical therapy (GDMT), consisting of a 30-day supply of rescue and triple-therapy inhalers, at discharge for patients with AECOPD.

Hospitals

Hospitals Compounding Pharmacies Vaccines Immunization

A Review of Oral Cephalosporins for Common Outpatient Infections

Pharmacy Times

JULY 25, 2025

Updated September 21, 2022. Centers for Disease Control and Prevention. Accessed March 5, 2025. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Department of Veterans Affairs Immunization Compounding Pharmacies

IsaKRD Induction Achieves 95% Response Rate in Multiple Myeloma

Pharmacy Times

JULY 8, 2025

May 4, 2022. Multiple myeloma. Cleveland Clinic. Accessed July 8, 2025. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!

Compounding Pharmacies

Compounding Pharmacies Immunization Specialty Pharmacies Compounding

Hypertension: A Silent Killer Requiring Novel Therapies

Pharmacy Times

JULY 19, 2025

A new drug application for lorundrostat is expected to be filed with the FDA in 2025. Lancet 2022; 400:1927-1937. The most frequent dose limiting adverse effect is hyperkalemia which is dose-related with an incidence of 5% to 7%. mg/d, 1 mg/d, 2 mg/d, and placebo for 12 weeks. 17 The placebo-subtracted reductions in sBP were 8.1

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Compounding Pharmacies Vaccines Immunization

Secondary Analysis Investigates Spillover Effects of Antibiotic Audit and Feedback

Pharmacy Times

JULY 16, 2025

The trial was conducted from January 2021 to December 2022, with a feedback letter sent on or after January 2022, including physicians that were randomly assigned in a 4 to 1 allocation. The misuse and overuse of antimicrobials to treat, prevent, and control infections has influenced the spread of AMR.

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Specialty Pharmacies

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

JUNE 23, 2025

The Orange Book is the reference, and it allows the FDA to declare something [to be] therapeutically equivalent. The FDA Approval Process Within the FDA approval process, the 505(b)(1) new drug application (NDA) submission pathway is the pathway by which new drugs are able to seek approval.

FDA

FDA Compounding Pharmacies Dosage Hospitals

Breaking New Ground in Migraine Prevention: Eptinezumab-jjmr

Pharmacy Times

JULY 2, 2025

On February 21, 2020, the FDA approved eptinezumab-jjmr (Vyepti; Lundbeck) as the first intravenous migraine preventative treatment for adults. Clinical trials showed eptinezumab-jjmr's efficacy in reducing migraine days and acute medication use, with benefits emerging within 24 hours.

Compounding Pharmacies

Compounding Pharmacies FDA Immunization Specialty Pharmacies

Because Ned Said: New Technology Helps Prevent Opioid Overdose

Pharmacy Times

JUNE 9, 2025

FDA approval of LIMITX for broader use could significantly impact opioid misuse prevention and save lives. Or, as FDA officials like to call it, “multiple tablet ingestion”—I guess it sounds better to them. trillion economic impact in 2020. SHOW MORE A novel solution can strategically control the release of the drug in vivo.

Compounding Pharmacies

Compounding Pharmacies Compounding Immunization FDA

Invest a Few Minutes in Inhaler Counseling

Pharmacy Times

JULY 23, 2025

link] 2022 global strategy for prevention, diagnosis, and management of COPD. Updated 2022. Lancet Respir Med.2022;10(5):447-458. 2022;10(5):447-458. doi:10.1016/S2213-2600(21)00511-7 Global strategy for asthma management and prevention. Accessed June 6,2025. Global Initiative for Asthma. Accessed June 6, 2025. 2023;17:259-272.

Hospitals

Hospitals Compounding Pharmacies Immunization FDA

Zanubrutinib Linked to Lower Infection Risk Than Venetoclax Plus Obinutuzumab in Real-World CLL/SLL Study

Pharmacy Times

JULY 9, 2025

However, patients with CLL/SLL typically have a higher risk of serious infection due to their compromised immune systems, raising concerns about the association between CLL/SLL-directed therapies and serious infection risks.

Immunization

Immunization Compounding Pharmacies Hospitals Specialty Pharmacies

Managing Tardive Dyskinesia With VMAT2 Inhibitors in Clinical Practice

Pharmacy Times

JULY 28, 2025

1 Vesicular monoamine transporter type 2 (VMAT2) inhibitors are the only FDA-approved treatment options. 6 A third VMAT2 inhibitor, tetrabenazine (Xenazine; Lundbeck Pharmaceuticals LLC), is also on the market but is only FDA approved for the treatment of Huntington disease (HD) chorea.

Compounding Pharmacies

Compounding Pharmacies Compounding Insurance Immunization

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Pharmacy Times

JUNE 19, 2025

2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025. With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings.

Compounding

Compounding Compounding Pharmacies FDA Immunization

New Online Competency Modules Standardize CPA Pharmacist Training at Academic Medical Center

Pharmacy Times

JUNE 9, 2025

Impact of community pharmacist-led interventions in chronic disease management on clinical, utilization, and economic outcomes: An umbrella review. Res Social Admin Pharm. 2020;16(9):1155-1165. doi:10.1016/j.sapharm.2019.12.016 2019.12.016 3. ASHP Statement on Professionalism. American Society of Health-System Pharmacists. Accessed June 9, 2025.

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Chemotherapy

Study Confirms Interchangeability of Hulio, Biosimilar of Humira, in Severe Chronic Plaque Psoriasis

Pharmacy Times

JUNE 24, 2025

SHOW MORE Hulio shows comparable efficacy and safety to Humira in treating chronic plaque psoriasis, supporting its FDA interchangeability status. The authors noted that these results support the FDA-granted interchangeability status of Hulio.

Compounding Pharmacies

Compounding Pharmacies FDA Immunization Compounding

Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike

Pharmacy Times

JULY 10, 2025

Medication Adherence Requires Personalized Communication Alva emphasized that effective counseling about medications—especially those with intimidating FDA warnings—requires compassionate, patient-centered communication.

Specialty Pharmacies

Specialty Pharmacies Vaccines Immunization Compounding Pharmacies

OTC Assessments With Recommendations and Counseling Should Be a Billable Encounter

Pharmacy Times

JUNE 17, 2025

OTC Use Saves Billions From Cost-Effective Products and Encounters Image credit: Amina | stock.adobe.com A 2022 publication purported $167 billion in savings in ancillary health care cost avoidance through the widespread use of OTC products in the United States. November 2022. REFERENCES The power of OTCs to provide consumer value.

Compounding Pharmacies

Compounding Pharmacies Drug Utilization Review Immunization Compounding

Pharmacists' Guide to Selection and Use of At-Home Blood Pressure Monitors

Pharmacy Times

JULY 30, 2025

In 2022, HTN was cited as a primary or contributing cause of 685,875 deaths in the United States. According to the CDC, HTN is defined as consistent readings of systolic blood pressure greater than 130 mm Hg or a diastolic blood pressure greater than 80 mm Hg.1 1 According to CDC data, an estimated 48.1% million individuals.

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Compounding

GLP-1s Lower Mortality, Neurodegeneration Risks

Drug Topics

JULY 25, 2025

Another notable detail from this study was that tirzepatide wasn’t FDA-approved until 2022, midway through the study period, possibly owing much of the GLP-1 benefits to semaglutide rather than tirzepatide.

Specialty Pharmacies

Specialty Pharmacies Compounding Independent Pharmacies Patient Care

ADA 2025: Advances in Type 2 Diabetes Management With Tirzepatide

Pharmacy Times

JUNE 23, 2025

1 Image credit: Cynthia | stock.adobe.com The discussion featured Vivian Fonseca, MD, of the Tulane University School of Medicine, who presented an overview of tirzepatide based on the FDA-approved label and clinical guidelines. He was joined by Laura, a patient who began tirzepatide treatment shortly after being diagnosed with T2D.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Compounding Pharmacies Immunization FDA

Mitomycin Intravesical Solution Receives FDA Approval for Non-Muscle Invasive Bladder Cancer

Pharmacy Times

JUNE 12, 2025

Mitomycin intravesical solution (Zusduri, UroGen Pharma) was approved by the FDA for treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

FDA

FDA Compounding Pharmacies Vaccines Immunization

Ropeginterferon Alfa 2b Is Well-Tolerated, Efficacious in Treatment of Prefibrotic Myelofibrosis

Pharmacy Times

JUNE 30, 2025

Updated October 6, 2022. FDA approves ropeginterferon alfa-2b-njft for polycythemia vera. REFERENCES 1. Ropeginterferon alfa 2b for early myelofibrosis. Accessed June 30, 2025. ASCO 2025 delivers insights into future of myelofibrosis care. Pharmacy Times. June 3, 2025. Accessed June 30, 2025. November 12, 2021.

Compounding Pharmacies

Compounding Pharmacies Immunization Compounding Specialty Pharmacies

Prescribing Cascades Can Often Lead to Polypharmacy for Older Adults

Drug Topics

JULY 30, 2025

Prescribing cascades can be appropriate when the combination has a positive benefit-risk balance, but if the ratio is negative, it would be inappropriate, explained authors in a separate study published in Deutsches Ärzteblatt International in 2022.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Specialty Pharmacies Independent Pharmacies Vaccines

FDA Posts Slate of Seven Warning Letters Following Company Inspections

PharmTech

JUNE 12, 2025

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS). American Behavioral Research Institute Boca Raton, Fla. – Amish Origins Management Worland, Wy. –

FDA

FDA Dosage Compounding Labelling

ADA: Vertex closer to weaning type 1 diabetics off insulin

pharmaphorum

JUNE 24, 2025

Skip to main content Tuesday 24 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies FDA Immunization

Op-Ed: Celebrate Direct-to-Career Paths and Primary Care Pharmacy Practice

Pharmacy Times

JUNE 10, 2025

North American Pharmacist Licensure Examination Passing Rates for 2022-2024 Graduates. Accreditation Standards and Key Elements for the Professional Program in Pharmacy Leading to the Doctor of Pharmacy Degree. July 1, 2024. Accessed June 6, 2025. National Association of Boards of Pharmacy. January 21, 2025. Accessed June 6, 2025.

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Compounding

Psychiatric Medication Adherence in Patients Experiencing Homelessness

Pharmacy Times

JULY 17, 2025

Reviewing Medication Adherence According to the WeAllCount Census for 2022 to 2023, 6 homelessness in San Diego increased by 22% (from 8427 to 10,264 individuals).

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Hospitals Compounding Pharmacies Documentation

TRE-5151 Receives FDA Fast Track Designation in Combination With Radiation Therapy for Prostate Cancer

Pharmacy Times

JULY 14, 2025

SHOW MORE FDA fast-tracks TRE-515 for advanced prostate cancer, combining it with radiation therapy to enhance treatment outcomes and patient care. The FDA has granted fast track designation to TRE-515 (Trethera Corporation), a novel drug, in combination with radiation therapy for the treatment of prostate cancer.

FDA

FDA Compounding Pharmacies Compounding Immunization

Do We Really Pay More for Prescription Drugs in the United States?

Pharmacy Times

JUNE 12, 2025

Biden’s 2022 Inflation Reduction Act (IRA), creating an out-of-pocket spending cap of $2000 starting in 2025, and Part D has become a very generous pharmacy benefit. A 2024 RAND study using 2022 data found that among Organisation for Economic Co-operation and Development (OECD) countries (comparably developed nations), the US paid 4.22

Community Pharmacies

Community Pharmacies Hospitals Compounding Pharmacies Vaccines

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

PharmTech

JUNE 24, 2025

In May 2024, the US Food and Drug Administration (FDA) approved Moderna’s next-generation base-modified mRNA-lipid nanoparticle (LNP) respiratory syncytial virus (RSV) vaccine mRESVIA (mRNA-1345) in adults aged 60 years and older with lower respiratory tract disease (5). falciparum malaria.

Vaccines

Vaccines Dosage FDA Immunization

FDA Approves Twice-Yearly Lenacapavir for HIV Preexposure Prophylaxis

Pharmacy Times

JUNE 18, 2025

The FDA has approved lenacapavir (Yeztugo; Gilead Sciences), a twice-yearly injectable HIV-1 capsid inhibitor, for the prevention of HIV as preexposure prophylaxis (PrEP), according to reports from NBC News, USA Today, and CNBC and a news release from Gilead Sciences.

FDA

FDA Compounding Pharmacies Immunization Compounding

Is Fluoride Friend or Foe?

Pharmacy Times

JUNE 25, 2025

The FDA plans to remove concentrated fluoride prescription products due to toxicity and neurocognitive concerns. 7 On May 13, 2025, the FDA issued a news release indicating it is taking action to remove concentrated fluoride prescription drug products from the market.

Compounding Pharmacies

Compounding Pharmacies FDA Immunization Hospitals

Patients Allege Home Delivery Pharmacy Failed Timely Notification of Data Breach

Pharmacy Times

JUNE 24, 2025

Image credit: neirfy | stock.adobe.com In February 2022, 9 months after the initial discovery and 13 months after the breach, the pharmacy began notifying customers of a breach in its computer information. REFERENCE Webb v Injured Workers Pharmacy, LLC, 1:22-cv-10797-RGS (ED Mass 2022).

Mail-Order Pharmacies

Mail-Order Pharmacies Compounding Pharmacies Vaccines Immunization

Pneumococcal Vaccine Rates Low Despite Updated Recommendations

FDA Approves Insulin Aspart-Xjhz as First Interchangeable Biosimilar to NovoLog

Trending Sources

Pharmacist Involvement Helps Reduce Time to A1c Target

CGM Usage Improves Glycemic, Psychosocial Outcomes for Type 1 Diabetes | ADA 2025

Financial Burden for Patients With Type 2 Diabetes Higher Than Those Without

Help Turn Occasional Shoppers into Loyal Customers by Investing in the Front End

4 vitamins for post-COVID fatigue

COVID-19 Pandemic Reduced Gaps in Pneumococcal Vaccination in Medicare Enrollees, But Lowered Overall Uptake

The Changing Landscape of Pharmacy Accessibility

Under the Weather: Unpacking the Impact of the 2024-2025 Influenza Season

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Pharmacists Push Forward: Innovative Clinical Solutions Highlighted at McKesson ideaShare 2025

Transitions of Care Pharmacists Mitigate Readmission Rates for COPD

A Review of Oral Cephalosporins for Common Outpatient Infections

IsaKRD Induction Achieves 95% Response Rate in Multiple Myeloma

Hypertension: A Silent Killer Requiring Novel Therapies

Secondary Analysis Investigates Spillover Effects of Antibiotic Audit and Feedback

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Breaking New Ground in Migraine Prevention: Eptinezumab-jjmr

Because Ned Said: New Technology Helps Prevent Opioid Overdose

Invest a Few Minutes in Inhaler Counseling

Zanubrutinib Linked to Lower Infection Risk Than Venetoclax Plus Obinutuzumab in Real-World CLL/SLL Study

Managing Tardive Dyskinesia With VMAT2 Inhibitors in Clinical Practice

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

New Online Competency Modules Standardize CPA Pharmacist Training at Academic Medical Center

Study Confirms Interchangeability of Hulio, Biosimilar of Humira, in Severe Chronic Plaque Psoriasis

Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike

OTC Assessments With Recommendations and Counseling Should Be a Billable Encounter

Pharmacists' Guide to Selection and Use of At-Home Blood Pressure Monitors

GLP-1s Lower Mortality, Neurodegeneration Risks

ADA 2025: Advances in Type 2 Diabetes Management With Tirzepatide

Mitomycin Intravesical Solution Receives FDA Approval for Non-Muscle Invasive Bladder Cancer

Ropeginterferon Alfa 2b Is Well-Tolerated, Efficacious in Treatment of Prefibrotic Myelofibrosis

Prescribing Cascades Can Often Lead to Polypharmacy for Older Adults

FDA Posts Slate of Seven Warning Letters Following Company Inspections

ADA: Vertex closer to weaning type 1 diabetics off insulin

Op-Ed: Celebrate Direct-to-Career Paths and Primary Care Pharmacy Practice

Psychiatric Medication Adherence in Patients Experiencing Homelessness

TRE-5151 Receives FDA Fast Track Designation in Combination With Radiation Therapy for Prostate Cancer

Do We Really Pay More for Prescription Drugs in the United States?

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

FDA Approves Twice-Yearly Lenacapavir for HIV Preexposure Prophylaxis

Is Fluoride Friend or Foe?

Patients Allege Home Delivery Pharmacy Failed Timely Notification of Data Breach

Stay Connected